Moderna Inc. ($MRNA) Stock Forecast: Up 8.2% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company known for its innovative mRNA technology, particularly in the development of vaccines and personalized cancer treatments. The stock had a strong bullish movement today.

Why is Moderna Inc. going up?

MRNA stock is up 8.2% on Jan 22, 2026 20:00

• Moderna's stock surged by 4% following the groundbreaking five-year follow-up data for their mRNA cancer vaccine, showing a significant reduction in the risk of relapse or death in high-risk melanoma patients. This success not only boosted investor confidence in Moderna's technology but also solidified its position as a major player in oncology.
• The announcement of Moderna curbing investments in vaccine trials due to US backlash had a positive impact on the stock, with shares jumping by 10.16% in morning trading. This strategic shift towards personalized cancer treatments in response to regulatory hurdles demonstrates the company's adaptability and focus on long-term growth.
• The partnership between Bristol Myers Squibb and Janux Therapeutics in developing novel T cell engagers for solid tumors may have indirectly contributed to Moderna's bullish movement by highlighting the potential in oncology treatments, further fueling optimism in the biotech sector.
• Overall, Moderna's bullish market movement today can be attributed to its groundbreaking cancer vaccine data, strategic shift towards personalized treatments, and positive investor sentiment towards advancements in oncology therapies.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally

Moderna and Merck announced groundbreaking five-year follow-up data for their experimental mRNA cancer vaccine, demonstrating a 49% reduction in the risk of relapse or death in high-risk melanoma patients when combined with Keytruda. This clinical success propelled Moderna's stock up 4% and validated mRNA technology's potential beyond infectious diseases, establishing a new benchmark for personalized cancer treatment. The data protects Keytruda's market share for Merck and positions Moderna as a major player in oncology, marking a paradigm shift in individualized neoantigen therapies.

http://markets.chroniclejournal.com/chroniclejournal/article/marketminute-2026-1-22-moderna-and-merck-solidify-oncology-leadership-as-five-year-melanoma-data-fuels-market-rally

Bristol Myers buys into Janux’s ‘masked’ T cell engagers

Bristol Myers Squibb has partnered with Janux Therapeutics in a deal potentially worth $850 million to develop "masked" T cell engagers for solid tumors. Janux will receive $50 million upfront and lead preclinical development for the novel tumor-activated therapeutic, which aims to overcome the side effects and limitations of traditional T cell engagers. This deal serves as validation for Janux's technology, though investor confidence will hinge on future positive updates from its lead programs.

https://www.biopharmadive.com/news/janux-bristol-myers-partnership-t-cell-engagers-cancer/810227/

Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV

Moderna CEO Stephane Bancel announced the company will curb investments in new late-stage vaccine trials due to growing opposition and lack of support from U.S. officials, including regulatory delays. Bancel noted that it's difficult to see a return on investment without access to the U.S. market, especially with Health and Human Services Secretary Robert F. Kennedy Jr. implementing policies that limit vaccination recommendations and funding for mRNA research. Following the announcement, shares of Moderna jumped 10.16% in morning trading.

https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-curbing-investments-vaccine-trials-due-us-backlash-ceo-tells-bloomberg-2026-01-22/

Moderna is curbing investment in vaccine trials due to US backlash

Moderna's CEO, Stéphane Bancel, announced that the company will limit investment in new late-stage vaccine trials due to growing opposition and regulatory hurdles from US officials. Bancel stated that the current environment makes it impossible to achieve a return on investment in the US market. This decision comes as Moderna, which previously focused on COVID-19 vaccines, attempts to pivot towards personalized cancer treatments amid a decline in its COVID-related business.

https://www.bostonglobe.com/2026/01/22/business/moderna-investment-vaccine-trials/

Cavco Industries stock hits all-time high at 709.56 USD

Cavco Industries Inc. stock reached a new all-time high of $709.56, reflecting a 47.93% increase over the past year and indicating strong investor confidence. The company, a leader in manufactured housing with a market capitalization of $5.51 billion, boasts a perfect Piotroski Score of 9 and recently surpassed Wall Street expectations for its Q2 fiscal year 2026 earnings and revenue. Despite appearing slightly overvalued by InvestingPro Fair Value metrics, its robust financial health and strategic growth are evident.

https://www.investing.com/news/company-news/cavco-industries-stock-hits-alltime-high-at-70956-usd-93CH-4460814

Trending Today

Axie Infinity ($AXS) Crypto Forecast: Up 5.7% Today

Silver ($XAG) Commodity Forecast: Up 6.3% Today

McCormick & Company Incorporated ($MKC) Stock Forecast: Down 8.0% Today

Datadog Inc. ($DDOG) Stock Forecast: Up 6.5% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Up 5.7% Today

Abbott Laboratories ($ABT) Stock Forecast: Down 10.2% Today

Meta Platforms, Inc. ($META) Stock Forecast: Up 5.0% Today

Macy's Inc ($M) Stock Forecast: Down 5.0% Today

Fiverr International Ltd. ($FVRR) Stock Forecast: Up 5.4% Today

Autodesk Inc. ($ADSK) Stock Forecast: Up 5.1% Today

Moderna Inc. Price History

16.00.2026 - MRNA Stock was up 6.6%

• Moderna witnessed a significant surge in its stock performance recently.
• The notable uptick in the market's reaction is linked to Moderna's optimistic preliminary sales projection for 2025 and favorable business prospects for 2026 onwards. These projections involve updated forecasts for operating expenses, improved cash reserves, and anticipated milestones in its product pipeline, such as upcoming regulatory submissions for novel vaccines and advancements in personalized cancer treatments.
• Despite the projected decrease in revenue due to declining demand for COVID vaccines, Moderna's strategic announcements have bolstered investor confidence in its future growth trajectory.
• The recent invalidation of a patent owned by Arbutus Biopharma, a company engaged in legal disputes with Moderna, could have positively influenced Moderna's stock price by potentially resolving some legal uncertainties for Moderna in the European market.

16.00.2026 - MRNA Stock was up 6.1%

• Moderna's optimistic outlook today is linked to its increased full-year 2025 revenue guidance to $1.9 billion, demonstrating significant growth potential.
• The positive trajectory is supported by Moderna's cost-cutting initiatives, an enhanced cash balance projection, and the ongoing phase three melanoma trial identified as a key driver for 2026 by RBC Capital.
• The decline in Arbutus Biopharma's stock value, stemming from a patent dispute with Moderna, may have inadvertently influenced Moderna's upward trend as investors may view Moderna as solidifying its competitive standing in the biopharmaceutical sector.

15.00.2026 - MRNA Stock was down 5.0%

• Moderna's stocks saw a downward trend today, potentially as investors took profits after a 17% jump post the positive initial financial results for 2025.
• There are concerns among analysts and investors regarding Moderna's shift away from solely focusing on COVID-19 vaccines to a more extensive pharmaceutical range, particularly in light of upcoming critical events like the Phase 3 cancer vaccine trial outcome and patent dispute.
• The recent downgrade of Absci Corporation (ABSI) by a financial institution could have impacted the market sentiment surrounding biotech firms like Moderna, underscoring the sector's inherent risks.
• Despite the recent decline in stock value, Moderna's strategic evolution and ongoing progress in its pipeline projects suggest that it could maintain a significant position in the pharmaceutical landscape over the long haul.

14.00.2026 - MRNA Stock was up 13.7%

• Moderna's stock saw a significant increase today due to an optimistic revenue outlook for 2026, anticipating up to $1.9 billion in revenue and potential vaccine approvals.
• Moderna's positive performance contrasts with the challenges faced by Apellis Pharmaceuticals, whose stock prices have declined despite positive revenue updates, reflecting market sentiment discrepancies.
• The recent acquisition offer by BioNTech for CureVac has brought stability to CureVac's stock, underscoring the significance of strategic partnerships in the biotech field.
• The upbeat movement in Moderna's stock might also be influenced by the growing focus on vaccine manufacturers like Novavax, as the CDC notes a surge in respiratory ailments, creating a favorable landscape for vaccine-related companies.

14.00.2026 - MRNA Stock was up 6.2%

• Moderna's stock saw a significant 17% increase after announcing strong preliminary financial results for full-year 2025, surpassing revenue expectations and predicting growth for 2026.
• Investor confidence in Moderna's future prospects grew as the market reacted positively to the company's shift towards a multi-product respiratory franchise and personalized cancer treatments.
• The bullish trend was influenced by expectations surrounding upcoming events like the Phase 3 cancer vaccine trial results and a patent trial in late 2026, with potential implications for Moderna's market position and valuation.
• Moderna's strategies to lower operating costs, achieve cash flow breakeven by 2028, and advance its pipeline, notably in seasonal vaccines, oncology, and rare diseases, further bolstered investor optimism and drove up the stock price.

21.00.2026 - MRNA Stock was up 16.9%

• Moderna's bullish movement today could be attributed to the broader positive sentiment in the cell and gene therapy market, driven by technological advancements and increasing demand for personalized medicine.
• Analysts' bullish outlook on Merck & Co. (MRK) and its potential acquisition of Revolution Medicines to strengthen its oncology pipeline may have positively influenced investor confidence in the biotech sector, including Moderna.
• The significant vaccine delivery licensing deal involving Pfizer and Novavax might have also boosted investor optimism in the biopharmaceutical industry, reflecting positively on Moderna's innovative approaches in vaccine development.
• Overall, the positive market movements in the biotech and pharmaceutical sectors, coupled with strategic advancements and collaborations within the industry, likely contributed to Moderna's strong bullish performance today.

21.00.2026 - MRNA Stock was up 5.5%

• Analysts are optimistic about Merck & Co. (MRK), with talk of a possible acquisition of Revolution Medicines enhancing positivity in the healthcare industry. This upbeat sentiment may have influenced the rise of Moderna's stock.
• The collaboration between Pfizer and Novavax on vaccine delivery technology showcases the competitive and ever-evolving landscape of the vaccine sector. This partnership potentially contributed to the favorable outlook towards Moderna.
• Moderna's strategic expansion into oncology, accompanied by encouraging data on its cancer therapy, has captured the attention of investors. The company's foray into areas beyond infectious disease vaccines might have played a part in its recent market upswing.
• Despite cautious views from BofA Securities on Moderna's stock value, the promising clinical results for its cancer vaccine Intismeran may have overshadowed apprehensions, leading to the positive momentum in the market.

21.00.2026 - MRNA Stock was up 11.6%

• The bullish movement in Moderna's stock today is influenced by the positive reception of the five-year follow-up data from its Phase IIb trial for a personalized mRNA-based cancer therapy, showing promising results for high-risk melanoma patients.
• Analyst sentiment toward Moderna remains optimistic, with BofA Securities recently raising its price target. Despite concerns about the stock valuation exceeding target levels and potential challenges in the oncology market, long-term confidence driven by strategic shifts and partnerships is boosting investor morale.
• Market movements within the biotechnology sector, such as news of acquisitions and licensing agreements by competitors like Merck and Novavax, may have also contributed to Moderna's positive momentum as investors recognize growth opportunities in the industry.
• Moderna's strategic focus on oncology, along with progress in its pipeline and favorable analyst outlook, positions the company well for future growth and innovation in the healthcare sector.

22.00.2026 - MRNA Stock was up 15.0%

• Moderna's bullish movement could be attributed to positive sentiment surrounding the company's COVID-19 vaccine sales and ongoing efforts in vaccine development.
• The market may be reacting favorably to the news of a global restructuring, potentially indicating investor confidence in companies adapting to optimize operations.
• Steady stock performance and positive outlook from an analyst firm could be contributing to a positive overall sentiment in the healthcare sector, benefiting companies like Moderna.
• A stock hitting a 52-week high and the positive analyst price target revisions could be boosting investor interest in the biotech sector, indirectly benefiting Moderna as well.

22.00.2026 - MRNA Stock was up 10.6%

• Moderna's bullish movement today could be attributed to positive sentiment surrounding the broader biotech sector and the company's ongoing efforts in vaccine development.
• The bullish market movement may also be influenced by the news of Bristol Myers partnering with Janux Therapeutics to develop novel tumor-activated therapeutics, highlighting the potential for innovative approaches in the healthcare industry.
• Additionally, the strong performance of other healthcare companies like Liquidia Technologies hitting an all-time high could have created a positive ripple effect in the sector, boosting investor confidence in Moderna's growth prospects.
• Overall, Moderna's bullish trend today seems to be driven by a combination of sector-wide optimism, positive developments in the healthcare industry, and potentially favorable market conditions for biotech companies.

22.00.2026 - MRNA Stock was up 12.0%

• The positive sentiment surrounding the efficacy and demand for Moderna's COVID-19 vaccine, as well as advancements in its pipeline for mRNA-based therapies, likely fueled the recent bullish movement.
• The collaboration between Janux Therapeutics and Bristol Myers Squibb could have played a role in boosting investor interest in biotech companies like Moderna.
• Abbott Laboratories' stock decline following revenue estimates miss may have indirectly benefited Moderna as investors potentially sought out companies with stronger growth potential.
• The selling of Merck & Co., Inc. shares by Bailard Inc. and other hedge funds may have shifted investments towards promising opportunities like Moderna, contributing to its bullish performance.

22.00.2026 - MRNA Stock was up 8.2%

• Moderna's stock surged by 4% following the groundbreaking five-year follow-up data for their mRNA cancer vaccine, showing a significant reduction in the risk of relapse or death in high-risk melanoma patients. This success not only boosted investor confidence in Moderna's technology but also solidified its position as a major player in oncology.
• The announcement of Moderna curbing investments in vaccine trials due to US backlash had a positive impact on the stock, with shares jumping by 10.16% in morning trading. This strategic shift towards personalized cancer treatments in response to regulatory hurdles demonstrates the company's adaptability and focus on long-term growth.
• The partnership between Bristol Myers Squibb and Janux Therapeutics in developing novel T cell engagers for solid tumors may have indirectly contributed to Moderna's bullish movement by highlighting the potential in oncology treatments, further fueling optimism in the biotech sector.
• Overall, Moderna's bullish market movement today can be attributed to its groundbreaking cancer vaccine data, strategic shift towards personalized treatments, and positive investor sentiment towards advancements in oncology therapies.